{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:32:37Z","timestamp":1788838357766,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biopha.2022.113974","type":"journal-article","created":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:58:49Z","timestamp":1667609929000},"page":"113974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro"],"prefix":"10.1016","volume":"156","author":[{"given":"Nicola L.","family":"Wilke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane Onambele","family":"Abodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corazon","family":"Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerico","family":"Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Jakupec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Keppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram","family":"Prokop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113974_bib1","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1158\/1535-7163.MCT-06-0285","article-title":"Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition","volume":"5","author":"Chitambar","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113974_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLM.2005.n.026","article-title":"Activity of gallium nitrate in refractory peripheral T-cell lymphoma","volume":"6","author":"Huang","year":"2005","journal-title":"Clin. Lymphoma"},{"key":"10.1016\/j.biopha.2022.113974_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0093-7754(03)00173-8","article-title":"Gallium nitrate in the treatment of lymphoma","volume":"30","author":"Straus","year":"2003","journal-title":"Semin Oncol."},{"key":"10.1016\/j.biopha.2022.113974_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1124\/jpet.107.126342","article-title":"Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate","volume":"322","author":"Chitambar","year":"2007","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113974_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2010.02.034","article-title":"A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells","volume":"34","author":"Chitambar","year":"2010","journal-title":"Leuk. Res"},{"key":"10.1016\/j.biopha.2022.113974_bib6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/jid.2014.476","article-title":"Gallium Maltolate Inhibits Human Cutaneous T-Cell Lymphoma Tumor Development in Mice","volume":"135","author":"Wu","year":"2015","journal-title":"J. Invest Dermatol."},{"key":"10.1016\/j.biopha.2022.113974_bib7","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4155\/fmc.12.69","article-title":"Gallium-containing anticancer compounds","volume":"4","author":"Chitambar","year":"2012","journal-title":"Future Med Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5414\/CPP43590","article-title":"Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV)","volume":"43","author":"Hofheinz","year":"2005","journal-title":"Int J. Clin. Pharm. Ther."},{"key":"10.1016\/j.biopha.2022.113974_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00775-014-1211-9","article-title":"Interaction of the anticancer gallium(III) complexes of 8-hydroxyquinoline and maltol with human serum proteins","volume":"20","author":"Enyedy","year":"2015","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib10","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1021\/jm3005459","article-title":"X-ray absorption spectroscopy of an investigational anticancer gallium(III) drug: interaction with serum proteins, elemental distribution pattern, and coordination of the compound in tissue","volume":"55","author":"Hummer","year":"2012","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1039\/b902861g","article-title":"Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects","volume":"1","author":"Timerbaev","year":"2009","journal-title":"Metallomics"},{"key":"10.1016\/j.biopha.2022.113974_bib12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/chem.201604516","article-title":"Response profiling using shotgun proteomics enables global metallodrug mechanisms of action to be established","volume":"23","author":"Kreutz","year":"2017","journal-title":"Chem. \u2013 A Eur. J."},{"key":"10.1016\/j.biopha.2022.113974_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173613","article-title":"AP-002: A novel inhibitor of osteoclast differentiation and function without disruption of osteogenesis","volume":"889","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113974_bib14","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1535-7163.MCT-14-0087","article-title":"Calpain-Mediated Integrin Deregulation as a Novel Mode of Action for the Anticancer Gallium Compound KP46","volume":"13","author":"Jungwirth","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113974_bib15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.18632\/oncotarget.6233","article-title":"Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy","volume":"7","author":"Wilfinger","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113974_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-017-0527-z","article-title":"Distinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition","volume":"36","author":"Kubista","year":"2017","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113974_bib17","first-page":"110","article-title":"Synergistic antiproliferative effects of tris(8-quinolinolato)gallium(III) (KP46) in combination with platinum drugs in ovarian and colon carcinoma cells","volume":"10","author":"Jakupec","year":"2008","journal-title":"Met. Ions Biol. Med."},{"key":"10.1016\/j.biopha.2022.113974_bib18","unstructured":"Altum Pharmaceuticals Inc. A Phase 1\/2 Dose Escalation Study of AP-002 In Patients with Advanced or Recurrent Solid Tumors (Clinical trial registration No. NCT04143789). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04143789\u3009 (accessed on 2022\u201310-25)."},{"key":"10.1016\/j.biopha.2022.113974_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CMR.0b013e32832b272d","article-title":"The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines","volume":"19","author":"Valiahdi","year":"2009","journal-title":"Melanoma Res"},{"key":"10.1016\/j.biopha.2022.113974_bib20","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1182\/blood.V97.5.1378","article-title":"Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95\/Fas receptor-ligand interaction and occurs downstream of caspase-3","volume":"97","author":"Wieder","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113974_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","article-title":"Detection of Necrosis by Release of Lactate Dehydrogenase (LDH) Activity","volume":"979","author":"Chan","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2022.113974_bib22","first-page":"2016","article-title":"Quantitation of Apoptosis and Necrosis by Annexin V Binding, Propidium Iodide Uptake, and Flow Cytometry","author":"Crowley","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.biopha.2022.113974_bib23","doi-asserted-by":"crossref","DOI":"10.3791\/2597","article-title":"Modified Annexin V\/Propidium Iodide Apoptosis Assay for Accurate Assessment of Cell Death","author":"Rieger","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2022.113974_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-60327-017-5_2","article-title":"Flow cytometry-based apoptosis detection","volume":"559","author":"Wlodkowic","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2022.113974_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","article-title":"A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry","volume":"139","author":"Nicoletti","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2022.113974_bib26","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biopha.2022.113974_bib27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113974_bib28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.biopha.2022.113974_bib29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0014-5793(94)00433-1","article-title":"Identification of a putative membrane-interacting domain of CTP:phosphocholine cytidylyltransferase from rat liver","volume":"345","author":"Wieder","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2022.113974_bib30","first-page":"3","article-title":"Apoptosis, oncosis, and necrosis. An overview of cell death","volume":"146","author":"Majno","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.113974_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2022.113974_bib32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nm1263","article-title":"Caspase-independent cell death","volume":"11","author":"Kroemer","year":"2005","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.113974_bib33","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/MMBR.64.4.821-846.2000","article-title":"Proteases for cell suicide: functions and regulation of caspases","volume":"64","author":"Chang","year":"2000","journal-title":"Microbiol Mol. Biol. Rev."},{"key":"10.1016\/j.biopha.2022.113974_bib34","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1745-7270.2005.00108.x","article-title":"Caspase family proteases and apoptosis","volume":"37","author":"Fan","year":"2005","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"key":"10.1016\/j.biopha.2022.113974_bib35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113974_bib36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00432-010-0924-6","article-title":"Iron containing anti-tumoral agents: unexpected apoptosis-inducing activity of a ferrocene amino acid derivative","volume":"137","author":"Kater","year":"2011","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113974_bib37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00432-018-2592-x","article-title":"Metal-free salan-type compound induces apoptosis and overcomes multidrug resistance in leukemic and lymphoma cells in vitro","volume":"144","author":"Dragoun","year":"2018","journal-title":"J. Cancer Res Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.113974_bib38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.281.5381.1309","article-title":"Mitochondria and apoptosis","volume":"281","author":"Green","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113974_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1044-5323(03)00031-9","article-title":"The CD95 type I\/type II model","volume":"15","author":"Barnhart","year":"2003","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.biopha.2022.113974_bib40","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1074\/jbc.274.12.7987","article-title":"Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs","volume":"274","author":"Micheau","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib41","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/sj.cdd.4400866","article-title":"An apoptosis signaling pathway induced by the death domain of FADD selectively kills normal but not cancerous prostate epithelial cells","volume":"8","author":"Morgan","year":"2001","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.113974_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41420-019-0144-z","article-title":"The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme","volume":"5","author":"Kaya-Aksoy","year":"2019","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2022.113974_bib43","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c01021","article-title":"Gold(I) Bis(1,2,3-triazol-5-ylidene) Complexes as Promising Selective Anticancer Compounds","author":"Schlagintweit","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1023\/A:1011379307472","article-title":"XIAP: Apoptotic brake and promising therapeutic target 9","volume":"6","author":"Holcik","year":"2001","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2022.113974_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1023\/A:1009616228304","article-title":"Role of reactive oxygen species (ROS) in apoptosis induction","volume":"5","author":"Simon","year":"2000","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2022.113974_bib46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s12033-010-9321-2","article-title":"Multiple drug resistance mechanisms in cancer","volume":"46","author":"Baguley","year":"2010","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.biopha.2022.113974_bib47","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.biopha.2022.113974_bib48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152013804487380","article-title":"New insight into p-glycoprotein as a drug target","volume":"13","author":"Breier","year":"2013","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib49","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0959-8049(96)00057-3","article-title":"P-glycoprotein--a mediator of multidrug resistance in tumour cells","volume":"32A","author":"Germann","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2022.113974_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0959-437X(96)80091-8","article-title":"P-glycoprotein and multidrug resistance","volume":"6","author":"Gottesman","year":"1996","journal-title":"Curr. Opin. Genet Dev."},{"key":"10.1016\/j.biopha.2022.113974_bib51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2174\/138161282005140214165212","article-title":"ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development","volume":"20","author":"Choi","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2022.113974_bib52","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1021\/jm100801e","article-title":"Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties","volume":"53","author":"Rubbiani","year":"2010","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","article-title":"Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis","volume":"575","author":"Fritsch","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113974_bib54","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2008.11.023","article-title":"Caspase-8 in cancer biology and therapy","volume":"281","author":"Fulda","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2022.113974_bib55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1054\/drup.2001.0223","article-title":"The role of caspase-8 in resistance to cancer chemotherapy","volume":"4","author":"Kim","year":"2001","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.biopha.2022.113974_bib56","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2174\/1871520615666150113123039","article-title":"Combined anticancer therapies: an overview of the latest applications","volume":"15","author":"Piccolo","year":"2015","journal-title":"Anticancer Agents Med Chem."},{"key":"10.1016\/j.biopha.2022.113974_bib57","unstructured":"Burkhardt, B., W\u00f6\u00dfmann, W., 2017, S1-Leitlinie 025\/013: Non-Hodgkin-Lymphome im Kindes- und Jugendalter. \u3008https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/025\u2013013l_S1_Non-Hodgkin-Lymphome_NHL_2017\u201305.pdf\u3009 (accessed 11.1.21)."},{"key":"10.1016\/j.biopha.2022.113974_bib58","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113974_bib59","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: results of the FAB\/LMB 96 international study*","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2022.113974_bib60","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113974_bib61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2004-03-0973","article-title":"The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95","volume":"105","author":"Woessmann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113974_bib62","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1476-5381.2011.01780.x","article-title":"Gallium compound GaQ3-induced Ca2+ signalling triggers p53-dependent and -independent apoptosis in cancer cells","volume":"166","author":"Gogna","year":"2012","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2022.113974_bib63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.pathmechdis.3.121806.151456","article-title":"The inflammatory response to cell death","volume":"3","author":"Rock","year":"2008","journal-title":"Annu Rev. Pathol."},{"key":"10.1016\/j.biopha.2022.113974_bib64","doi-asserted-by":"crossref","unstructured":"Kirkin, V., Joos, S., Z\u00f6rnig, M., 2004, The role of Bcl-2 family members in tumorigenesis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Bcl-2 family members: integrators of survival and death signals in physiology and pathology 1644, 229\u2013249. https:\/\/doi.org\/10.1016\/j.bbamcr.2003.08.009.","DOI":"10.1016\/j.bbamcr.2003.08.009"},{"key":"10.1016\/j.biopha.2022.113974_bib65","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1038\/onc.2008.307","article-title":"Bcl-2 family proteins and cancer","volume":"27","author":"Yip","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2022.113974_bib66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113974_bib67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00689638","article-title":"P-glycoprotein, multidrug resistance and tumor progression","volume":"13","author":"Bradley","year":"1994","journal-title":"Cancer Metast Rev."},{"key":"10.1016\/j.biopha.2022.113974_bib68","first-page":"6410","article-title":"Identification of HRK as a Target of Epigenetic Inactivation in Colorectal and Gastric Cancer","volume":"9","author":"Obata","year":"2003","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113974_bib69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00401-005-1065-x","article-title":"Frequent HRK inactivation associated with low apoptotic index in secondary glioblastomas","volume":"110","author":"Nakamura","year":"2005","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2022.113974_bib70","first-page":"212","article-title":"Defective Expression of HRK is Associated with Promoter Methylation in Primary Central Nervous System Lymphomas","volume":"70","author":"Nakamura","year":"2006","journal-title":"OCL"},{"key":"10.1016\/j.biopha.2022.113974_bib71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/pros.20600","article-title":"HRK inactivation associated with promoter methylation and LOH in prostate cancer","volume":"68","author":"Higuchi","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.biopha.2022.113974_bib72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajpath.2012.09.018","article-title":"Synergistic Silencing by Promoter Methylation and Reduced AP-2\u03b1 Transactivation of the Proapoptotic HRK Gene Confers Apoptosis Resistance and Enhanced Tumor Growth","volume":"182","author":"Xu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2022.113974_bib73","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10495-022-01734-z","article-title":"XIAP as a multifaceted molecule in Cellular Signaling","volume":"27","author":"Hanifeh","year":"2022","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2022.113974_bib74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.embor.7400795","article-title":"Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family","volume":"7","author":"Eckelman","year":"2006","journal-title":"EMBO Rep."},{"key":"10.1016\/j.biopha.2022.113974_bib75","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3390\/biom10111493","article-title":"XIAP\u2019s profile in human cancer","volume":"10","author":"Tu","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113974_bib76","first-page":"1796","article-title":"Expression and Prognostic Significance of IAP-Family Genes in Human Cancers and Myeloid Leukemias","volume":"6","author":"Tamm","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113974_bib77","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10495-017-1429-4","article-title":"Inhibitors of apoptosis: clinical implications in cancer","volume":"22","author":"Mohamed","year":"2017","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2022.113974_bib78","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.22393","article-title":"Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence","volume":"48","author":"Shi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2022.113974_bib79","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.3390\/cancers13112807","article-title":"Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy","volume":"13","author":"Devi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2022.113974_bib80","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7150\/jca.28229","article-title":"Prognostic Value of XIAP Level in Patients with Various Cancers: A Systematic Review and Meta-Analysis","volume":"10","author":"Gao","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.biopha.2022.113974_bib81","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1158\/1078-0432.CCR-03-0642","article-title":"High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid Leukemia","volume":"10","author":"Tamm","year":"2004","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113974_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2020.118761","article-title":"Expression of nuclear XIAP associates with cell growth and drug resistance and confers poor prognosis in breast cancer","volume":"1867","author":"Delbue","year":"2020","journal-title":"Biochim Biophys. Acta Mol. Cell Res"},{"key":"10.1016\/j.biopha.2022.113974_bib83","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pbc.22541","article-title":"XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL","volume":"55","author":"Hundsdoerfer","year":"2010","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2022.113974_bib84","first-page":"133","article-title":"Expression of the IAPs in multidrug resistant tumor cells","volume":"11","author":"Notarbartolo","year":"2004","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2022.113974_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3389\/fonc.2014.00197","article-title":"X-linked inhibitor of apoptosis protein \u2013 a critical death resistance regulator and therapeutic target for personalized cancer therapy","volume":"4","author":"Obexer","year":"2014","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2022.113974_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100712","article-title":"Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance","volume":"52","author":"Shahar","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.biopha.2022.113974_bib87","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations improve therapeutic selectivity","volume":"27","author":"Leh\u00e0r","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2022.113974_bib88","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222013634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T11:57:20Z","timestamp":1778241440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222013634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":88,"alternative-id":["S0753332222013634"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113974","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gallium complex KP46 sensitizes resistant leukemia cells and overcomes Bcl-2-induced multidrug resistance in lymphoma cells via upregulation of Harakiri and downregulation of XIAP in vitro","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113974"}}